Patents Examined by Kahsay Habte
-
Patent number: 11827644Abstract: The present invention relates to a pyrazine derivative, an application thereof in inhibiting SHP2, and a compound of formula (I) or pharmaceutically acceptable salts, esters, isomers, solvates, prodrugs or isotope labels thereof. The structure of the compound of formula (I) is as follows. The novel pyrazine derivative provided by the present invention has excellent inhibition of SHP2 activity and can be used to prevent and/or treat non-receptor protein tyrosine phosphatase-mediated or dependent diseases or disorders.Type: GrantFiled: January 25, 2023Date of Patent: November 28, 2023Assignee: SUZHOU GENHOUSE PHARMACEUTICAL CO., LTDInventors: Haifeng Sun, Kuifeng Wang, Tao Zhang, Mengnan Ma, Jinchang Lu
-
Patent number: 11820762Abstract: The subject invention pertains to compositions and methods for treating neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), multiple sclerosis, epilepsy, stroke, alcohol withdrawal, progressive supranuclear palsy (PSP), Pick's disease (PiD), corticobasal degeneration (CBD), frontotemporal dementia or parkinsonism linked to chromosome 17 (FTDP-17). The methods of the subject invention further relate to methods of fermentation of bacterial cells and methods of tautomerization of the subject compounds.Type: GrantFiled: September 15, 2021Date of Patent: November 21, 2023Assignees: The Hong Kong University of Science and Technology, Southern Marine Science and Engineering Guangdong Laboratory (Guangzhou)Inventors: Pei-Yuan Qian, Aifang Cheng, Changdong Liu, Wenkang Ye, Guang Zhu
-
Patent number: 11820776Abstract: The present disclosure relates to novel processes for the preparation of short acting benzodiazepines as well as to novel intermediates in this process. More particularly the disclosure relates to processes and intermediates for preparation of Methyl 3-[(4S)-8-bromo-1-methyl-6-(pyridin-2-yl)-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate, commonly known as Remimazolam. The present disclosure also relates to solid state forms of Remimazolam salts, processes for the preparation thereof, pharmaceutical formulations/compositions thereof, and methods of use thereof.Type: GrantFiled: May 24, 2021Date of Patent: November 21, 2023Assignee: ASSIA CHEMICAL INDUSTRIES LTD.Inventors: Dolitzky Ben-Zion, Mendelovici Marioara, Bodkhe Arjun Rajaram, Mane Ganesh Shivaji, Samala Rajamouli Srihari, Joshi Ashutosh Vijay, Parven Kumar Luthra, Amit Singh, Anantha Rajmohan Muthusamy
-
Patent number: 11814371Abstract: The present application relates to the field of medicine. Specifically, disclosed are a compound of formula (I), a preparation method therefor, and a pharmaceutical composition comprising the compound.Type: GrantFiled: March 4, 2021Date of Patent: November 14, 2023Assignee: MEDSHINE DISCOVERY INC.Inventors: Guanglong Sun, Chunli Shen, Chengde Wu, Shuhui Chen
-
Patent number: 11814399Abstract: A synthetic protocol to use a thiourea or urea compound and auric chloride as starting materials to obtain thiazole and benzothiazole derivatives. The synthesis can be conducted at room temperature and the final compound can result from cyclization of the thiourea or urea compound in the presence of an Au salt from the auric chloride.Type: GrantFiled: April 7, 2023Date of Patent: November 14, 2023Assignee: KING FAISAL UNIVERSITYInventors: Awal Noor, Ezzat Khan, Umar Ali Khan
-
Patent number: 11807650Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.Type: GrantFiled: January 27, 2022Date of Patent: November 7, 2023Assignee: Novartis AGInventors: David R. Anderson, Robert Volkmann, Frank Menniti, Christopher Fanger, Yuelian Xu
-
Patent number: 11807607Abstract: The aminocarbazole compounds are antibacterial agents. The emergence of drug-resistant bacteria calls for constant development of new antibacterial agents with the aim of generating medicaments that are potent against drug sensitive and resistant bacteria and are well tolerated. The present compounds are not only new, but have very valuable antimicrobial properties. These compounds showed a broad spectrum of activity against gram-positive and gram-negative bacteria, as well tuberculosis mycobacteria. They also showed potent activity against drug-resistant bacteria, such as MRSA and VRSA. The molecular target of these compounds was identified as DNA Gyrase B. Based on their pharmacological profiles, the present compounds may find important clinical applications for severe infectious diseases and tuberculosis.Type: GrantFiled: March 29, 2023Date of Patent: November 7, 2023Assignee: KING FAISAL UNIVERSITYInventors: Christophe Tratrat, Michelyne Haroun
-
Patent number: 11807648Abstract: The present invention provides a process for preparing a compound of the formula (II): wherein R2 is unsubstituted alkyl, characterized by reacting a compound of the formula (I): wherein R1 is hydrogen or a protecting group other than unsubstituted alkyl, with a compound of the formula: R2—OH, wherein R2 is as defined above, in the presence of a sodium salt and/or a magnesium salt.Type: GrantFiled: January 19, 2022Date of Patent: November 7, 2023Assignee: SHIONOGI & CO., LTD.Inventor: Setsuya Shibahara
-
Patent number: 11807635Abstract: Disclosed is a nitrile derivative compound represented by formula (I), a stereoisomer, a deuterated product, a co-crystal, a solvate or a pharmaceutically acceptable salt thereof, wherein each group is as defined in the description. The compound has dipeptidyl peptidase 1 inhibitory activity and can be used to prepare a drug for treating diseases including obstructive airway diseases, bronchiectasis, cystic fibrosis, asthma, emphysema, and chronic obstructive pulmonary diseases.Type: GrantFiled: October 28, 2022Date of Patent: November 7, 2023Assignee: Haisco Pharmaceuticals Pte. Ltd.Inventors: Yao Li, Zongjun Shi, Guobiao Zhang, Lei Chen, Wenjing Wang, Xiaobo Zhang, Dengyu Zheng, Bo Xu, Xin Liu, Yajun Wang, Fei Ye, Pingming Tang, Jia Ni, Chen Zhang, Pangke Yan
-
Patent number: 11795179Abstract: Novel first-in-class imidazothiazole- and imidazooxazole-based potent and selective HER4 kinase inhibitors for therapeutic formulations and methods for treating cancer.Type: GrantFiled: December 30, 2020Date of Patent: October 24, 2023Assignee: UNIVERSITY OF SHARJAHInventor: Mohammed El-Gamal
-
Patent number: 11779912Abstract: This invention relates generally to olefin metathesis catalyst compounds, to the preparation of such compounds, compositions comprising such compounds, methods of using such compounds, articles of manufacture comprising such compounds, and the use of such compounds in the metathesis of olefins and olefin compounds. The invention has utility in the fields of catalysts, organic synthesis, polymer chemistry, and industrial and fine chemicals industry.Type: GrantFiled: August 27, 2021Date of Patent: October 10, 2023Assignees: UMICORE AG & Co. KG, CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: Adam M. Johns, Jessica R. Herron, Richard L. Pederson, Bryan A. Fiamengo, Jennifer A. Beerman, Tzu-Pin Lin, Crystal K. Chu, Robert H. Grubbs
-
Patent number: 11780809Abstract: The N-(6-substitutedcarbazol-2-yl) acetamide compounds are antibacterial agents. The emergence of drug-resistant bacteria calls for constant development of new antibacterial agents with the aim of generating medicaments that are potent against drug sensitive and resistant bacteria and are well tolerated. The present compounds are not only new, but have very valuable antimicrobial properties. These compounds showed a broad spectrum of activity against gram-positive and gram-negative bacteria, as well tuberculosis mycobacteria. They also showed potent activity against drug-resistant bacteria, such as MRSA and VRSA. The molecular target of these compounds was identified as DNA Gyrase B. Based on their pharmacological profiles, the present compounds may find important clinical applications for severe infectious diseases and tuberculosis.Type: GrantFiled: March 9, 2023Date of Patent: October 10, 2023Assignee: KING FAISAL UNIVERSITYInventors: Christophe Tratrat, Michelyne Haroun
-
Patent number: 11773111Abstract: Novel dual 5-LO inhibitors of well validated electrophilic Michael acceptors and nitrogen-heterocycles are presented and designed to maintain specific structural features of currently known dual 5-LO inhibitors and to overcome their drawbacks. The Michael acceptor scaffold will act as a carrier and will provide a stable anchorage via covalent binding to cysteine/histidine residues within the catalytic cleft and/or the surface interface of the 5-LO; whereas, the nitrogen-heterocycles will ensure the access to the Fe(II) catalytic center. These combinations offer potential for more than one mode of iron chelation and 5-LO inhibition.Type: GrantFiled: November 29, 2022Date of Patent: October 3, 2023Assignee: KING FAISAL UNIVERSITYInventors: Saadeldin Elsayed Ibrahim Shabaan, Hany Mohamed Abd El-Lateef Ahmed
-
Patent number: 11773052Abstract: Provided are a donor-acceptor type compound having a novel structure and its use.Type: GrantFiled: March 2, 2018Date of Patent: October 3, 2023Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Hideo Nagashima, Atsushi Tahara, Ikumi Kitahara, Yoichiro Kuninobu
-
Patent number: 11773086Abstract: The present invention is directed to compounds, compositions, and methods for inhibiting drug-efflux pumps. The compounds, compositions, and methods can be used for enhancing the activity of therapeutic agents that are efflux pump substrates and for the treatment of drug-resistant diseases or disorders, such as microbial infections and cancers.Type: GrantFiled: August 31, 2021Date of Patent: October 3, 2023Assignees: TRUSTEES OF BOSTON UNIVERSITY, THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTOInventors: Lauren E. Brown, Kaddy Camara, Leah E. Cowen, John A. Porco, Jr., Kali Rae Iyer
-
Patent number: 11759462Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.Type: GrantFiled: March 15, 2021Date of Patent: September 19, 2023Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner
-
Patent number: 11746095Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.Type: GrantFiled: May 6, 2022Date of Patent: September 5, 2023Assignee: KINNATE BIOPHARMA INC.Inventors: Stephen W. Kaldor, Toufike Kanouni, Eric Murphy, Jason Cox, Robert Kania
-
Patent number: 11746100Abstract: The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I? and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.Type: GrantFiled: April 28, 2021Date of Patent: September 5, 2023Assignee: Global Blood Therapeutics, Inc.Inventors: Qing Xu, Carsten Alt, Zhe Li, Shahul Nilar, Peter Michael Rademacher, Calvin Wesley Yee
-
Patent number: 11731964Abstract: The present invention generally relates to compounds as a new antibiotic to treat various infections, including infections caused by methicillin-resistant Staphylococcus aureus, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecalis and Clostridioides difficile. Pharmaceutical compositions and methods for treating those diseases are within the scope of this invention.Type: GrantFiled: March 29, 2019Date of Patent: August 22, 2023Assignee: Purdue Research FoundationInventors: Herman O. Sintim, Mohamed Seleem, Clement Opoku-Temeng, Haroon Taj Mohammad, George Naclerio
-
Patent number: 11731939Abstract: The indole-based chalcone compounds are antibacterial agents. The emergence of drug-resistant bacteria calls for constant development of new antibacterial agents with the aim of generating medicaments that are potent against drug sensitive and resistant bacteria and are well tolerated. The present compounds are not only new, but have very valuable antimicrobial properties. These compounds showed a broad spectrum of activity against gram-positive and gram-negative bacteria, as well tuberculosis mycobacteria. They also showed potent activity against drug-resistant bacteria, such as MRSA and VRSA. The molecular target of these compounds was identified as DNA Gyrase B. Based on their pharmacological profiles, the present compounds may find important clinical applications for severe infectious diseases and tuberculosis.Type: GrantFiled: March 7, 2023Date of Patent: August 22, 2023Assignee: KING FAISAL UNIVERSITYInventors: Christophe Tratrat, Michelyne Haroun